ES2105643T3 - Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer. - Google Patents

Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.

Info

Publication number
ES2105643T3
ES2105643T3 ES94906748T ES94906748T ES2105643T3 ES 2105643 T3 ES2105643 T3 ES 2105643T3 ES 94906748 T ES94906748 T ES 94906748T ES 94906748 T ES94906748 T ES 94906748T ES 2105643 T3 ES2105643 T3 ES 2105643T3
Authority
ES
Spain
Prior art keywords
treatment
pct
tumours
naftoquinone
chlorofenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94906748T
Other languages
English (en)
Inventor
Alan Thomas Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2105643T3 publication Critical patent/ES2105643T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE 2-[4-(4CLOROFENIL)CICLOHEXIL]-3-HIDROXI-1,4-NAFTOQUINONA O DE UNA SAL FARMACEUTICAMENTE ACEPTABLE U OTRO DERIVADO FISIOLOGICAMENTE FUNCIONAL DE LA MISMA PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TUMORES DE ANIMALES, A COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES DE ANIMALES, A COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES, QUE CONTIENEN DICHO COMPUESTO COMO INGREDIENTE ACTIVO Y UN METODO PARA EL TRATAMIENTO DE TUMORES DE ANIMALES QUE CONSISTE EN ADMINISTRAR AL ANIMAL UNA CANTIDAD EFECTIVA DE DICHO COMPUESTO.
ES94906748T 1992-08-07 1993-08-06 Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer. Expired - Lifetime ES2105643T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929216859A GB9216859D0 (en) 1992-08-07 1992-08-07 Medicaments

Publications (1)

Publication Number Publication Date
ES2105643T3 true ES2105643T3 (es) 1997-10-16

Family

ID=10720039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94906748T Expired - Lifetime ES2105643T3 (es) 1992-08-07 1993-08-06 Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.

Country Status (11)

Country Link
US (1) US5567738A (es)
EP (1) EP0653936B1 (es)
JP (1) JPH07509710A (es)
KR (1) KR950702413A (es)
AT (1) ATE155343T1 (es)
AU (1) AU676687B2 (es)
CA (1) CA2141274A1 (es)
DE (1) DE69312297T2 (es)
ES (1) ES2105643T3 (es)
GB (1) GB9216859D0 (es)
WO (1) WO1994003163A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
WO2012153162A1 (en) 2011-05-12 2012-11-15 Lupin Limited Novel method for preparation of atovaquone
WO2013014486A1 (en) 2011-07-28 2013-01-31 Lupin Limited Improved synthesis of 2-(4-(4-chlorophenyl) cyclohex-1-enyl) -3, 4-dihydronaphthalen-1 (2h)-one; an intermediate for atovaquone
KR101990054B1 (ko) * 2017-04-25 2019-06-17 대구대학교 산학협력단 로손을 유효성분으로 포함하는 항암 조성물
KR20250130660A (ko) * 2023-01-19 2025-09-02 루미스타 바이오테크놀로지 아이엔씨. 칼슘 방출-활성화 칼슘 채널 또는 디스코이딘 도메인 수용체 2 관련 장애 또는 병태의 치료 또는 예방에서의 사용을 위한 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533648A (en) * 1949-03-05 1950-12-12 Joseph H Warburg Circular saw making
US3347742A (en) * 1965-05-28 1967-10-17 Merck & Co Inc 2-(4-cyclohexylcyclohexyl)-3-hydroxy-1, 4-naphthoquinone in controlling coccidiosis in poultry
US3367830A (en) * 1965-06-23 1968-02-06 Merck & Co Inc Controlling coccidiosis in poultry with 1,4-naphthoquinones
GB1141735A (en) * 1966-11-23 1969-01-29 Pfizer & Co C Pharmaceutical anti-tumor composition
US3655699A (en) * 1970-03-02 1972-04-11 Pfizer Analogues of lapachol as antitumor agents
GB1553424A (en) * 1976-02-10 1979-09-26 Wellcome Found Method of treating protozal diseases
IL56013A (en) * 1977-11-22 1983-06-15 Wellcome Found 2-cycloalkyl-3-hydroxy-1,4-naphthoquinone derivatives,their preparation and therapeutic compositions containing them
US4485116A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US4485117A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
NZ230313A (en) * 1988-08-16 1992-07-28 Wellcome Found Pharmaceutical formulations comprising a naphthoquinone adapted for nasal administration, naphthoquinone derivatives, preparation and use thereof
DE68912262T2 (de) * 1988-10-07 1994-05-11 Sakai Chemical Industry Co Katalysatoren und Verfahren zur Denitrierung.

Also Published As

Publication number Publication date
AU4722493A (en) 1994-03-03
EP0653936B1 (en) 1997-07-16
KR950702413A (ko) 1995-07-29
DE69312297D1 (de) 1997-08-21
US5567738A (en) 1996-10-22
CA2141274A1 (en) 1994-02-17
GB9216859D0 (en) 1992-09-23
WO1994003163A1 (en) 1994-02-17
DE69312297T2 (de) 1997-10-30
ATE155343T1 (de) 1997-08-15
EP0653936A1 (en) 1995-05-24
AU676687B2 (en) 1997-03-20
JPH07509710A (ja) 1995-10-26

Similar Documents

Publication Publication Date Title
DE69213010D1 (de) Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.
PT1040830E (pt) Medicamento para doencas neurodegenerativas
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
FI950403A0 (fi) Neurosuojaavia yhdisteitä
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
ATE80624T1 (de) Substituierte 2-acylpyridin-alpha-(n)hetarylhydrazone sowie diese enthaltende arzneimittel.
MX9304365A (es) Una forma de dosis osmotica para administrar tandospirona.
MC2142A1 (fr) Medicament contre la toxoplasmose
GB9126874D0 (en) Medicaments
BR9612316A (pt) Agente para profilaxia e tratamento de complicações diabéticas
MC2203A1 (fr) Medicament contre la cryptosporidiose
EA200400348A1 (ru) Цисплатиновые составы пониженной токсичности и способы их применения
GEP19970834B (en) 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.
PL447189A1 (pl) Nowe zastosowanie medyczne kwasu cynnabarynowego

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 653936

Country of ref document: ES